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involved in the endonuclease activity of the heterotrimeric 
influenza polymerase complex. The crystal structure of the 
magnesium complex of the o-vanillin thiosemicarbazone 
ligand 1 is also described. Moreover, docking studies of 
PA endonuclease with compounds 1 and 2 were performed, 
to further analyse the possible mechanism of action of this 
class of inhibitors.
Keywords Influenza virus · Thiosemicarbazone · 
Endonuclease · Metal chelation · Antiviral
Introduction
Currently available antiviral drugs to treat or prevent influ-
enza infections comprise two classes of agents: those tar-
geting the viral M2 ion-channel (amantadine and riman-
tadine) and those targeting the viral neuraminidase (NA) 
(zanamivir and oseltamivir). The M2 inhibitors have lim-
ited clinical utility because of worldwide spread of drug-
resistant mutant viruses among almost all influenza A virus 
subtypes, including the 2009 pandemic H1N1 virus [1–3]. 
Resistance is also a growing concern for oseltamivir [4]. 
Therefore, there is an urgent need for entirely novel antivi-
ral compounds with a different mode of action and target-
ing a critical step in the viral replication process [5]. The 
influenza virus genome consists of eight single-stranded 
(−)RNA segments, which are transcribed and replicated by 
the viral RNA-dependent RNA polymerase (RdRp) [6, 7]. 
This RdRp is widely recognized as a superior target for the 
development of new antivirals, since it is highly conserved 
among influenza A, B and C viruses, and its functions are 
essential for viral genome replication [8]. It is composed of 
three subunits: PA, PB1 and PB2. The endonuclease activ-
ity, which resides in the N-terminal part of PA (PA-Nter) [9, 
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10], is required to cleave host cell pre-mRNAs and produce 
the 5′-capped primers for transcription of the viral genomic 
RNA into mRNA (cap-snatching) [11]. Cap-snatching is 
an important event in the life cycle of all members of the 
Orthomyxoviridae family of viruses, including influenza 
A, B and C viruses. The host cell has no analogous activ-
ity; therefore, inhibitors of cap-snatching may be active 
against all influenza virus (sub)types and strains, including 
oseltamivir-resistant influenza viruses, without interfering 
with normal host cell functions.
Several X-ray crystallographic studies have been per-
formed on PA-Nter, revealing the presence of one [10, 12] 
or two [9, 13, 14] divalent metal ions within the active site 
(Fig. 1). The two-metal-ion model is also consistent with 
biochemical [15] and computational [16] findings. The ions 
identified by means of X-ray diffraction are magnesium(II) 
or manganese(II), depending on the crystallization condi-
tions. Considering the relative abundance of these two 
metal ions in the cell ([Mg2+] is about 1000 times higher 
than [Mn2+]), magnesium may be more biologically 
relevant.
Metal chelation has emerged as an efficient strat-
egy to develop new inhibitors of metal-dependent viral 
enzymes, the most illustrious example being the class of 
HIV integrase inhibitors, some of which have already been 
approved [17]. In the same way, development of PA-bind-
ing agents with metal-chelating properties may represent 
a successful strategy to tackle influenza infections. Sev-
eral chelating molecules have been identified as influenza 
endonuclease inhibitors, including 2,4-dioxobutanoic acid 
derivatives [18–20], 5-hydroxy-1,6-dihydropyrimidine-
4-carboxylic acids [12], flutimide and its derivatives [21], 
2-hydroxyphenyl amide derivatives [22] as well as tetramic 
acids [23] and 5-hydroxy pyrimidin-4-one derivatives [24] 
(Fig. 2).
Thiosemicarbazones (TSCs) possess a broad range of 
biological properties including antitumor, antimalarial and 
antimicrobial activity [25]; moreover, they have shown 
good antiviral activity against herpes simplex virus [26], 
vaccinia and cowpox virus [27], as well as HIV [28, 29]. 
The biological properties of TSCs are often related to 
chelation of metal ions [30] and, therefore, they could be 
good candidates as chelating inhibitors of influenza virus 
endonuclease. TSCs can coordinate to the metal centre 
in an N,S-bidentate mode, but when an additional coordi-
nating group is present, more diversified binding modes 
become possible [31]. In particular, the presence of the OH 
group in salicylaldehyde thiosemicarbazone derivatives 
might provide a more favourable coordination for hard 
metal ions like Mg2+ that prefers oxygen donor atoms.
In the present work, we report the synthesis of some 
salicylaldehyde thiosemicarbazone derivatives (1–6, Fig. 3) 
and their biological evaluation against influenza virus, both 
in enzymatic assays with influenza virus PA-Nter and in 
virus yield assays in MDCK cells. In order to investigate 
the role of the thiosemicarbazone moiety on activity, we 
also synthesized and tested compound 7, the hydrazone 
analogue of 2, the most active molecule in the thiosemicar-
bazone series.
To assess the role of metal chelation in their antivi-
ral mode of action, we have selected 1 and 2 (1 without 
activity and 2 with reasonable activity against the PA-Nter 
enzyme) and studied their interactions with Mg2+, the ion 
N N
N
O
N
O
O
O
N
O
O
N
M2+
M2+
O
Glu80
Asp108
Ile120
His41
O
O
N
Glu119
O
Fig. 1  Schematic representation of the metal-interacting residues 
within the catalytic site of influenza virus PA endonuclease, assuming 
the presence of two metal ions (see Ref. [12, 13])
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Fig. 2  Chemical structures of some prototype inhibitors of influenza 
virus endonuclease [19, 21, 24]
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that is probably involved in the endonuclease activity of the 
native influenza virus RdRp complex. The crystal structure 
of complex Mg(HL1)22CH3OH is also described (1, H2L
1). 
Finally, docking studies on compounds 1 and 2 in complex 
with PA-Nter endonuclease were performed, to better elu-
cidate the possible binding mode of these inhibitors.
Materials and methods
Chemistry
All reagents of commercial quality were used without fur-
ther purification. Purity of compounds was determined by 
elemental analysis and verified to be ≥95 % for all syn-
thesized molecules. NMR spectra were recorded at 25 °C 
on a Bruker Avance 400 FT spectrophotometer. The ATR-
IR spectra were recorded by means of a Nicolet-Nexus 
(Thermo Fisher) spectrophotometer using a diamond crys-
tal plate in the range of 4000–400 cm−1. Elemental analy-
ses were performed using a FlashEA 1112 series CHNS/O 
analyzer (Thermo Fisher) with gas-chromatographic sepa-
ration. Electrospray mass spectral analyses (ESI–MS) were 
performed with an electrospray ionization (ESI) time-of-
flight Micromass 4LCZ spectrometer. MS spectra were 
acquired in positive EI mode by means of a DEP-probe 
(Direct Exposure Probe) mounting on the tip a Re-filament 
with a DSQII Thermo Fisher apparatus, equipped with a 
single quadrupole analyzer.
Synthesis of the ligands
The TSCs 1–6 and the semicarbazone 7 were prepared fol-
lowing reported procedures [32]. Briefly, to a solution of 
the aldehyde in absolute ethanol, an equimolar amount of 
thiosemicarbazide was added, dissolved in the same sol-
vent. In the synthesis of 7, semicarbazide hydrochloride 
was used, which was suspended in ethanol and the pH 
adjusted to 7 using KOH 1 M. The mixture was refluxed for 
6 h, cooled at room temperature and concentrated in vac-
uum. The resulting precipitate was filtered off, washed with 
cold ethanol and dried in vacuum.
N‑(2‑Hydroxy‑)‑3‑methoxybenzylidenethiosemicarbazide 
(1, H2L
1) Yield = 71 %. 1H-NMR (DMSO-d6, 25 °C), δ: 
3.80 (s, 3H, OCH3), 6.77 (t, 1H; J = 7.9 Hz, ArH), 6.96 
(d, 1H, J = 7.8 Hz, ArH), 7.52 (d, 1H, J = 7.8 Hz, ArH), 
7.87 (s, br, 1H, NH), 8.09 (s, br, 1H, NH), 8.40 (s, 1H; 
HC=N), 9.20 (s, br, 1H, OH), 11.39 (s, br, 1H; NH). 1H-
NMR (MeOD-d4, 25 °C), δ: 3.90 (s, 3H, OCH3), 6.84 (t, 1H; 
J = 7.9 Hz, ArH), 6.99 (d, 1H, J = 7.8 Hz, ArH), 7.43 (d, 
1H, J = 7.8 Hz, ArH), 8.41 (s, 1H; HC=N). MS (EI, 70 eV), 
m/z (%) = 225.0 ([M]+, 100); IR (cm−1): νNH = 3459, 
3339; νOH = 3158 (br); νC=N = 1596; νC=S = 1532, 821; 
νOCH3 = 1258, 1056. Anal. Calcd. for C9H11N3O2S·0.5H2O: 
C 46.14; H 5.16; N 17.94. Found: C 45.92, H 4.82, N 18.24.
N‑(2,3‑Dihydroxybenzylidene)‑thiosemicarbazide (2, H2L
2) 
Yield = 75 %. 1H-NMR (DMSO-d6, 25 °C), δ: 6.63 (t, 1H; 
Fig. 3  Chemical structures of 
ligands 1–7 and the coordina-
tion modes a and b of 1–5, 
involving the OH groups
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J = 7.9 Hz, ArH), 6.79 (d, 1H, J = 7.8 Hz, ArH), 7.35 (d, 
1H, J = 7.5 Hz, ArH), 7.86 (s, br, 1H, NH), 8.08 (s, br, 
1H, NH), 8.36 (s, 1H; HC=N), 9.20 (s, vbr, 2H, OH), 11.37 
(s, br, 1H; NH). 1H-NMR (MeOD-d4, 25 °C), δ: 6.75 (t, 
J = 7.9 Hz, 1H), 6.86 (dd, J = 7.9, 1.6 Hz, 1H), 7.14 (d, 
J = 7.9 Hz, 1H), 8.30 (s, 1H, HC=N). MS (EI, 70 eV), m/z 
(%) = 210.9 ([M]+, 100); IR (cm−1): νNH = 3364, 3256; 
νOH = 3173 (br); νC=N = 1620; νC=S = 1539, 825. Anal. 
Calcd. for C8H9N3O2S·0.5H2O: C 43.63; H 4.58; N 19.08. 
Found: C 43.33, H 4.48, N 18.98.
N‑(2,4‑Dihydroxybenzylidene)‑thiosemicarbazide 
(3) Yield = 78 %. 1H-NMR (DMSO-d6, 25 °C), δ: 6.25–
6.29 (m, 2H; ArH), 7.67 (d, 1H, J = 8.4 Hz, ArH), 7.74 (s, 
br, 1H, NH), 7.94 (s, br, 1H, NH), 8.24 (s, 1H; HC=N), 9.78 
(s, br, 2H, OH), 11.17 (s, br, 1H; NH). MS (EI, 70 eV), m/z 
(%) = 211.0 ([M]+, 100); IR (cm−1): νNH = 3479, 3347; 
νOH = 3262, 3128 (br); νC=N = 1630; νC=S = 1582, 875. 
Anal. Calcd. for C8H9N3O2S 1/3H2O: C 44.23; H 4.48; N 
19.34. Found: C 43.94, H 4.05, N 19.18.
N‑(2,5‑Dihydroxybenzylidene)‑thiosemicarbazide 
(4) Yield = 85 %. 1H-NMR (DMSO-d6, 25 °C), δ: 6.68 
(m, 2H; ArH), 7.22 (s, 1H, ArH), 7.78 (s, br, 1H, NH), 8.07 
(s, br, 1H, NH), 8.30 (s, 1H; HC=N), 8.83 (s, br, 2H, OH), 
9.21 (s, br, 2H, OH), 11.33 (s, br, 1H; NH). MS (EI, 70 eV), 
m/z (%) = 211.0 ([M]+, 100); IR (cm−1): νNH = 3427, 3328; 
νOH = 3048, 3002 (br); νC=N = 1623; νC=S = 1559, 942. 
Anal. Calcd. for C8H9N3O2S 1/3H2O: C 44.23; H 4.48; N 
19.34. Found: C 44.11, H 4.39, N 19.18.
N‑(2‑Hydroxy‑5‑methoxybenzylidene)‑thiosemicarbazide 
(5) Yield = 63 %. 1H-NMR (DMSO-d6, 25 °C), δ: 
6.76–6.84 (m, 2H; ArH), 7.48 (s, 1H, ArH), 8.01 (s, br, 1H, 
NH), 8.13 (s, br, 1H, NH), 8.35 (s, 1H; HC=N), 9.44 (s, 
br, 2H, OH), 11.36 (s, br, 1H; NH). MS (EI, 70 eV), m/z 
(%) = 225.0 ([M]+, 100); IR (cm−1): νNH = 3412, 3304; 
νOH = 3120 (br); νC=N = 1626; νC=S = 1537, 821. Anal. 
Calcd. for C9H11N3O2S: C 47.99; H 4.92; N 18.65. Found: 
C 48.17, H 4.82, N 18.34.
N‑(3‑(1,1′‑Biphenyl)‑4‑carboxylic acid)‑thiosemicar‑
bazide (6) Yield = 51 %. 1H-NMR (DMSO-d6, 25 °C), 
δ: 7.53 (t, J = 8 Hz, 1H; ArH), 7.78 (m, 2H, ArH), 7.89 (d, 
J = 8 Hz, 2H, ArH), 8.03 (d, 2H, ArH), 8.13–8.26 (m, 4H, 
ArH + HC=N + NH2), 11.51 (s, br, 1H, NH), 13.00 (s, 
br, 1H, OH). MS (EI, 70 eV), m/z (%) = 298.9 ([M]+, 60); 
IR (cm−1): νNH+OH = 3432, 3263, 3143 (br); νC=N = 1606; 
νNH2 = 1535. Anal. Calcd. for C21H16N2O6S·1.5H2O: C 
55.21; H 4.94; N 12.88. Found: C 55.38, H 4.85, N 13.03.
N ‑ ( 2 , 3 ‑ D i h y d ro x y b e n z y l i d e n e ) ‑ s e m i c a r b a z i d e 
(7) Yield = 70 %. 1H-NMR (DMSO-d6, 25 °C), δ: 6.36 
(s, br, 2H, NH2), 6.64 (t, 1H; J = 7.9 Hz, ArH), 6.76 (d, 1H, 
J = 7.8 Hz, ArH), 7.17 (d, 1H, J = 7.5 Hz, ArH), 8.14 (s, 
1H; HC=N), 9.21, 9.39 (s, br, 2H, OH), 10.17 (s, br, 1H; 
NH). 1H-NMR (MeOD-d4, 25 °C), δ: 6.75 (t, J = 7.9 Hz, 
1H), 6.86 (dd, J = 7.9, 1.6 Hz, 1H), 7.14 (d, J = 7.9 Hz, 
1H), 8.30 (s, 1H, HC=N). MS (EI, 70 eV), m/z (%) = 195.0 
([M]+, 100); IR (cm−1): νNH = 3455, 3350; νOH = 3166 (br); 
νC=O = 1694; νC=N = 1592. Anal. Calcd. for C8H9N3O3: C 
49.23; H 4.65; N 21.53. Found: C 49.16, H 4.48, N 21.40.
Mg(HL1)2 2.5H2O (8) 0.5 mmol of H2L
1 was dissolved in 
20 ml of methanol and 4 eq. of NEt3 was added. The solu-
tion turned yellow and it was stirred at r.t. for 30 min; 0.5 eq. 
of magnesium acetate was added and the reaction mixture 
was stirred at r.t. for 4 h, concentrated in vacuum and cooled 
overnight. The precipitate was filtered off and washed with 
water. Crystals suitable for X-ray diffraction analysis were 
obtained by slow evaporation of the mother liquors at room 
temperature. Yield: 74 %. 1H-NMR (MeOD, 25 °C), δ: 
3.89 (s, 3H, OCH3); 6.84 (t, br, 1H, ArH), 6.98 (d, br, 1H, 
ArH), 7.42 (d, br, 1H, ArH), 8.40 (s, 1H, HC=N). MS–ESI, 
m/z (+, %) = 473 ([M + H]+, 40); 495 ([M + Na]+, 40). 
IR (cm−1): νNH = 3334 (br); νC=N = 1596; νC=S = 1534; 
νOCH3 = 1238, 1027. Anal. Calcd. for C18H20N6O4Mg 
2.5H2O: C 41.75, H 4.87, N 16.23, S 12.38. Found: C 41.30, 
H 4.75, N 16.12, S 12.97.
Mg(HL2)2 (9) 0.5 mmol of H2L
2 was dissolved in 20 ml 
of degassed methanol under nitrogen and 4 eq. of NEt3 was 
added. The solution turned yellow and it was stirred at r.t. 
for 30 min; 0.5 eq. of magnesium acetate was added and the 
reaction mixture was stirred at r.t. for 4 h, concentrated in 
vacuum and cooled overnight. The precipitate was filtered 
off under inert atmosphere, washed with water and kept 
under nitrogen. Both the solution and the solid turn dark if 
exposed to air. 1H-NMR (MeOD-d4, 25 °C), δ: 6.47 (s, br, 
2H), 6.81 (s, br, 1H), 8.12 (s, br, 1H, HC=N). MS–ESI, m/z 
(−,  %) = 443 ([M]−, 10); 210 ([HL2]−, 100). IR (cm−1): 
νNH+OH = 3275, 3164 (br); νC=N = 1568; νC=S = 1534.
X‑ray crystallography
Single crystals of 2 and of Mg(HL1)2·2CH3OH were 
selected and mounted on glass fibres to collect data on a 
SMART Breeze diffractometer. The crystals were kept at 
293 K during data collection. Table 1 reports crystal data 
and structure analysis. Using Olex2 [33], the structure 
was solved with the SIR2004 [34] structure solution pro-
gram using Direct Methods and refined with the ShelXL 
refinement package [35] using least squares minimisation. 
Anisotropic displacement parameters were refined for all 
non-hydrogen atoms. Hydrogen atoms were partly located 
on the Fourier difference map and partly introduced in 
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calculated positions riding on their carrier atoms. Hydro-
gen bonds were analysed with PARST97 [36] and the Cam-
bridge Structural Database software [37, 38] was used for 
the analysis of the crystal packing. Table 1 summarizes 
crystal data and structure determination results. Crys-
tallographic data (excluding structure factors) for 2 and 
Mg(HL1)2·2CH3OH have been deposited with the Cam-
bridge Crystallographic Data Centre as supplementary pub-
lication no. CCDC 1049845–1049846. Copies of the data 
can be obtained free of charge on application to CCDC, 12 
Union Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223-
336-033; e-mail: deposit@ccdc.cam.ac.uk).
Biology
Production of recombinant influenza virus PA‑Nter protein
The coding sequence for PA-Nter (i.e. residues 1–217 
from the PA protein of influenza virus strain A/X-31) was 
cloned in the pET28a(+) plasmid (Merck KGaA, Darm-
stadt, Germany) with an N-terminal 6xHis-tag, and this 
bacterial expression plasmid was transformed into E. 
coli BL21-CodonPlus cells (Agilent Technologies, Santa 
Clara, CA). These bacteria were grown to an OD of 0.6, 
when IPTG was added at a final concentration of 1 mM to 
induce expression of recombinant protein for 5 h at 37 °C. 
The bacterial cells were ruptured using a French press and 
the protein was purified by 6xHis-Ni–NTA chromatogra-
phy (Qiagen, Valencia, CA), followed by buffer exchange 
using PD-10 desalting columns (GE Healthcare, Diegem, 
Belgium) to keep the protein in storage buffer (50 mM 
Tris–HCl pH 8, 100 mM NaCl, 10 mM β-mercaptoethanol, 
50 % glycerol). Protein purity was verified by SDS-PAGE 
with Coomassie Blue staining, and protein concentration 
was determined by Bradford assay. Finally, the purified 
protein was divided in aliquots and stored at −80 °C.
Plasmid‑based endonuclease assay
The enzymatic PA-Nter assay was performed according 
to a published method [22] with minor modifications [20]. 
One microgram of recombinant PA-Nter was incubated 
Table 1  Crystal data and structure refinement for 2 and Mg(HL1)2·2CH3OH
Mg(HL1)2·2MeOH 2
Empirical formula C20H28MgN6O6S2 C10H15N3O3S
Formula weight 536.91 257.31
Temperature/K 293(2) 293
Crystal system Orthorhombic Monoclinic
Space group P2nn P21/c
a/Å 7.878(1) 9.3259(6)
b/Å 10.639(2) 13.5879(9)
c/Å 31.921(5) 10.1652(6)
α/° 90 90
β/° 90 101.2117(9)
γ/° 90 90
Volume/Å3 2675.4(7) 1263.5(1)
Z 4 4
ρcalc g/cm
3 1.333 1.353
μ, mm−1 0.267 0.257
F(000) 1128.0 544.0
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073)
2Θ range for data collection/° 2.552–44.106 4.452–63.216
Reflections collected 21,724 19,770
Independent reflections 3296 [Rint = 0.0818, Rsigma = 0.0481] 4033 [Rint = 0.0263, Rsigma = 0.0184]
Data/restraints/parameters 3296/7/326 4033/0/174
Goodness-of-fit on F2 1.073 1.031
Final R indexes [I ≥ 2σ (I)] R1 = 0.0702, wR2 = 0.1916 R1 = 0.0442, wR2 = 0.1267
Final R indexes [all data] R1 = 0.0855, wR2 = 0.2057 R1 = 0.0492, wR2 = 0.1311
Largest ΔF max/min/e Å−3 1.09/−0.38 0.81/−0.71
Flack parameter 0.43(7)
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with 1 μg (16.7 nM) of single-stranded circular DNA plas-
mid M13mp18 (Bayou Biolabs, Metairie, Louisiana) in 
the presence of the test compounds and at a final volume 
of 25 μL. The assay buffer contained 50 mM Tris–HCl pH 
8, 100 mM NaCl, 10 mM β-mercaptoethanol and 1 mM 
MnCl2. The reaction was incubated at 37 °C for 2 h and 
then stopped by heat inactivation (80 °C, 20 min). The 
endonucleolytic digestion of the plasmid was visualized 
by gel electrophoresis on a 1 % agarose gel with ethid-
ium bromide staining, and the amount of remaining intact 
plasmid was quantified by ImageQuant TL software (GE 
Healthcare).
The percentage inhibition of endonuclease activity was 
plotted against the compound concentration on a semi-log-
arithmic plot, using GraphPad Prism software (GraphPad 
Software, La Jolla, CA). Values were the mean ± S.E.M. 
of three independent experiments. The 50 % inhibitory 
concentrations (IC50) were obtained by nonlinear least 
squares regression analysis. The known PA-Nter inhibitor 
2,4-dioxo-4-phenylbutanoic acid (DPBA) was included as 
the reference compound.
Cells and media
Madin–Darby canine kidney (MDCK) cells (a kind gift 
from M. Matrosovich, Marburg, Germany) and human 
embryonic kidney 293T (HEK293T) cells (purchased from 
Thermo Scientific) were grown in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 10 % foetal 
calf serum (FCS), 1 mM sodium pyruvate and 0.075 % 
sodium bicarbonate. Virus experiments were performed 
in MDCK infection medium, consisting of Ultra MDCK 
medium (Lonza, Basel, Switzerland) supplemented with 
0.0225 % sodium bicarbonate, 2 mM l-glutamine and 
2 μg/mL tosyl phenylalanyl chloromethyl ketone (TPCK)-
treated trypsin (Sigma-Aldrich). The cells were incubated 
in a 5 % CO2 humidified atmosphere.
vRNP reconstitution assay
The assay to determine the inhibitory effect of the com-
pounds on reconstituted influenza virus vRNPs is 
described in more detail elsewhere [39, 40]. Briefly, the 
four relevant expression plasmids derived from influenza 
A/PR/8/34 (i.e. pVP-PB1, pVP-PB2, pVP-NP and pVP-
PA; generously donated by M. Kim [41], Korea Research 
Institute of Chemical Technology, Daejeon, South Korea) 
were combined with a firefly luciferase reporter plasmid 
(also a kind gift from M. Kim) and cotransfected into 
HEK293T cells using Lipofectamine 2000. After 24 h of 
incubation at 37 °C in the presence of the test compounds, 
luciferase activity was determined using the ONE-Glo 
luciferase assay system (Promega). The 50 % effective 
concentration (EC50) was defined as the compound con-
centration causing 50 % reduction in the vRNP-driven 
firefly luciferase signal, as compared to cells receiving 
medium instead of compound. These EC50 values were 
calculated by interpolation assuming a semi-log dose–
response effect. In parallel, the compound cytotoxicity, 
expressed as CC50 (50 % cytotoxic concentration) was 
determined using the spectrophotometric MTS cell viabil-
ity assay (CellTiter 96 AQueous One Solution Cell Prolif-
eration Assay; Promega). The CC50 values were defined 
as the compound concentration reducing cell viability in 
untransfected HEK293T cells by 50 %, as compared to the 
wells receiving medium instead of compound. Ribavirin 
was included as the reference compound.
Virus yield assay
To determine anti-influenza virus activity in cell culture, 
a virus yield assay was performed [40]. One day prior to 
infection, MDCK cells were seeded into 96-well plates at 
25,000 cells per well. At day 0, the test compounds were 
added at serial dilutions, immediately followed by infec-
tion with influenza A/PR/8/34 virus. The multiplicity of 
infection (MOI) was 150 CCID50 per well (50 % cell cul-
ture infectious dose; determined by the method of Reed and 
Muench [42]). After 24 h of incubation at 35 °C, the super-
natants were harvested and stored at −80 °C. The viral copy 
number in these samples was estimated by a one-step quan-
titative real-time reverse transcription (qRT)-PCR assay 
(CellsDirect One-Step qRT-PCR kit; Invitrogen, Life Tech-
nologies, Gent, Belgium), with influenza virus M1-specific 
primers and probe (see [43] for all details). An M1-plasmid 
standard was included to allow absolute quantification. 
The EC99 and EC90 values were calculated by interpolation 
from data of at least three experiments and defined as the 
compound concentration causing, respectively, a 2-log10 
and 1-log10 reduction in viral RNA (vRNA) copy number, 
as compared to the virus control receiving no compound. 
In parallel, uninfected MDCK cells were used to determine 
the CC50 values of the compounds after 24 h incubation, 
using the MTS cell viability assay (CellTiter 96 AQueous 
One Solution Cell Proliferation Assay; Promega). Ribavirin 
was included as the reference compound.
Computational studies
The crystal structure of PA endonuclease in complex with 
epigallocatechin-3-gallate was retrieved from the RCSB 
Protein Data Bank (entry code 4AWM). The ligand and 
water molecules were discarded and the hydrogens were 
added to protein by Discovery Studio 2. The epigallocat-
echin-3-gallate, L-742,001 and 2-(4-(1H-tetrazol-5-yl)
phenyl)-5-hydroxypyrimidin-4(3H)-one structures were 
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extracted from their X-ray complexes, and the other struc-
tures of the ligands were constructed using Discovery Stu-
dio 2.5.5 (Accelrys, Discovery Studio) and energy mini-
mized using the Smart Minimizer protocol (1000 steps) 
which combines the Steepest Descent and the Conjugate 
Gradient methods.
The ligands minimized in this way were docked in their 
corresponding proteins by means of Gold Suite 5.0.1 [44]. 
The region of interest used by Gold program was defined to 
contain the residues within 15 Å from the original position 
of the ligand in the X-ray structure. The side-chain of the 
residue Tyr24 was allowed to rotate according to the inter-
nal rotamer libraries in GOLD Suite 5.0.1. GoldScore was 
chosen as fitness function and the standard default setting 
was used in all calculations and the ligands were submit-
ted to 100 genetic algorithm runs. The “allow early ter-
mination” command was deactivated. Results differing by 
less than 0.75 Å in ligand-all atom RMSD were clustered 
together. The best GOLD-calculated conformation was 
used both for analysis and representation.
Results and discussion
Chemistry
The ligands 1–6 (Fig. 3) were easily prepared in high yields 
by condensation of the thiosemicarbazide and the substi-
tuted benzaldehyde; they were characterized by spectro-
scopic tools, mass spectrometry and elemental analysis. 2 
was also characterized by single crystal X-ray diffraction. 
In 6 the OH/OCH3 groups are substituted by a carboxylic 
moiety, which retains good affinity for magnesium ions, 
following a suggestion emerged in the research for new 
inhibitors of HIV RNase H [45], which has two magnesium 
ions in its active site. In the IR spectra of 1–6 the C = S 
stretching absorptions are at about 1530–1580 and 820–
940 cm−1; in the 1H-NMR spectra, the resonances of the 
iminic proton (about 8.0 ppm) and of the hydrazonic NH 
and of NH2 (11.3 ppm and 7.8–8.0 ppm, approximately) 
are evident. Isomerism around the C=N bond is possible, 
but in the 1H-NMR spectra registered in d6-DMSO there is 
only one set of signals: evidently, all the ligands are in the 
E form in solution. Even if these ligands can give rise to 
a thione-thiol equilibrium, no evidence was obtained about 
the presence of the thiolic form in solution. Analogous con-
siderations can be made for 7, the hydrazonic analogue of 
compound 2.
Ligands 1–5 are very versatile: they possess both soft 
and hard donor atoms and they can act as bidentate or tri-
dentate chelating ligands. Complexes of salicylaldimine 
thiosemicarbazones with divalent metals like Pd(II), Zn(II), 
Cu(II), Ni(II) have been studied previously [46–51], but 
little is known about their interactions with magnesium 
ions [52]. Magnesium is a hard Lewis acid and so coordi-
nation of the sulphur atom could be excluded. It is known 
that salicylaldimine ligands can be NO-coordinated to mag-
nesium (A, Fig. 3), but in 1 and 2, with two oxygen donors 
in ortho, coordination B (Fig. 3) is also plausible. Since 
chelation of the divalent metal cofactors within the active 
site of the influenza virus PA endonuclease provides the 
possible basis for their antiviral activity [17], we decided to 
clarify the coordination properties of two of these ligands 
(1 and 2, H2L
1 and H2L
2, respectively) towards Mg2+. The 
ligands were combined with magnesium acetate to react 
in the presence of triethylamine as a base to afford the 
corresponding metal complexes 8 and 9. It is worth not-
ing that, in the case of 2, the reaction was executed under 
inert atmosphere, since the reaction mixture became dark 
when exposed to air. In order to verify the influence of the 
metal to ligand ratio or the pH, different reaction conditions 
were used with 1 (1:1 and 1:2 metal to ligand ratio; up to 
4 equivalents of base), but only with a 1:2 metal to ligand 
ratio and in the presence of 4 equivalents of base, a metal 
complex was isolated.
The infrared spectrum of both 8 and 9 displays bands 
associated with the NH group (3163–3460 cm−1), thus indi-
cating that this functionality is not deprotonated. The bands 
associated with the C=S stretching are unaffected upon 
complexation; therefore, it can be assumed that this group is 
not involved in coordination, as confirmed by X-ray diffrac-
tion analysis on 8. In the IR spectrum of 8 the stretching of 
the methoxy group is slightly shifted compared to the free 
ligand, suggesting a possible involvement in coordination. 
The 1H-NMR spectrum of 8 registered in d6-DMSO shows 
the presence of two sets of signals: one set corresponds to 
the free ligand, while the second one corresponds to the 
metal complex. The use of a coordinating solvent, there-
fore, causes the partial decoordination of the ligand. On the 
contrary, in the 1H-NMR spectrum in MeOD, where the 
solubility is, however, low, there is a unique set of signals: 
the ligand coordinates to the metal in a bidentate fashion 
only when a poor coordinating solvent is present. The 1H-
NMR spectrum of 9 shows very broad signals, which might 
indicate that a fluxional behaviour can exist in solution. 
It is worth noting that complex 9 is not stable if exposed 
to air both in solution and at the solid state. Mass spectra 
confirmed the presence in solution of complexes of type 
M(HL)2 and elemental analysis confirmed the proposed sto-
ichiometry, Mg(HL1)2·2.5H2O, for 8.
X‑ray crystallography
Ligand 2 was crystallized from ethanol as the solvate form 
2·CH3CH2OH (Table 1). The molecular structure, shown 
in Fig. 4, is perfectly planar, and the thiosemicarbazone 
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chain is completely extended, with trans torsion angles 
larger than 175° along the chain. The cis configuration 
between the amide NH and the imidic CH favours the 
aggregation of coplanar molecular pairs by the interac-
tions between these groups and the sulphur (Fig. 4, bot-
tom) (N2–H…S1(i) = 3.401(1)Å, 167.2(1)°, C7–H…
S1(i) = 3.762(1)Å, 152.0(1)°, i = 1 − x, −y, 2 − z). The 
dimeric assembly is surrounded by ethanol molecules 
linked by hydrogen bonds to the hydroxyl groups of 2 
which act as donors: O2–H…O3(ii) = 2.816(2)Å, 141(2)°; 
O1-H…O3(iii) = 2.770(2)Å, 168(3)° (ii = 2 − x, y − 1/2, 
3/2 − z; iii = 2 − x, −y, 1 − z). The ethanol molecule in 
turn donates a hydrogen bond to the sulphur atom (O3–H…
S1(iv) = 3.218(1)Å, 158(2)°, iv = x + 1, y, z) while the 
−NH2 moiety donates a hydrogen bond to one hydroxyl 
group (N3–H…O2(v) = 3.013(2)Å, 178(2)°, v = 1 − x, 
1/2 + y, 3/2 − z), thus generating a three-dimensional 
hydrogen bond network.
Complex Mg(HL1)2·2CH3OH crystallizes from metha-
nol in the orthorhombic P2nn space group (Table 1). The 
neutral complex comprises two monodeprotonated (HL1)− 
ligands coordinated in a bidentate mode to the magne-
sium cation by means of the methoxy group and of the 
deprotonated hydroxyl group, forming two planar five-
membered chelation rings; two cis methanol molecules 
complete the octahedral coordination (Fig. 5) and the over-
all complex molecule has a pseudo twofold rotation axis 
relating the two ligands and the two methanol molecules.
The mer configuration of the two bidentate ligand con-
fers optical activity to the complex; the crystal is, however, 
racemic due to the presence of reflection planes. The thio-
semicarbazone arms are protonated on the amidic nitrogen 
and are noticeably distorted due to intramolecular inter-
actions. In fact the amide NH and the imidic CH groups 
are in trans configuration, and the latter is also turned 
away from the hydroxyl group, in contrast to the situa-
tion observed for the free ligand 2 (H2L
2), whose molecu-
lar structure is comparable to 1 (H2L
1). The torsion angles 
along the chains of the two ligands (HL1)− in the complex 
differ significantly from the 0/180° value of the extended 
conformation of the free ligand, reported in parentheses: 
C1–C2–C8–N1 = 150/155°(−5°), C2–C8–N1–N2 = 7/3° 
(180°), C8–N1–N2–C9 = −166/−162°(175°), N1–N2–
C9–N3 = 9/5°(−2°). These conformational distortions 
are mainly due to strong intramolecular hydrogen bonds 
between the amidic NH and the coordinated deprotonated 
Fig. 4  Molecular structure and 
labelling of 2, with thermal 
ellipsoids drawn at the 50 % 
probability level. Bottom 
supramolecular aggregation of 2 
. CH3CH2OH in the solid, with 
dotted hydrogen bonds
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hydroxyl oxygens (N2–H…O1 = 2.582(1)Å, 147(1)°; 
N11–H…O10 = 2.589(1)Å, 153(1)°), and between 
the coordinated methanol molecules and the sulphur 
atoms (O100–H…S1 = 3.189(1)Å, 155(1)°; O200–H…
S2 = 3.212(1)Å, 159(1)°). The –NH2 moiety is involved in 
an intermolecular hydrogen bond to the sulphur atom gen-
erating an R22(8) ring (Fig. 5, bottom) which expands in 
ribbons along the diagonal ab (N3–H…S1(vi) = 3.410(1)
Å, 162(1)°; N12–H…S2(vii) = 3.503(2)Å, 166(1)°, 
vi = x + 1, y − 1, z, vii = x − 1, y + 1, z). In both the free 
ligand and the complex the sulphur atoms are significantly 
involved in intermolecular interactions where they act as 
acceptors from –OH and –NH groups.
Biological activity
Compounds 1–6 were evaluated for their ability to inhibit 
endonuclease activity in an enzymatic assay with recom-
binant PA-Nter, and the results are presented in Table 2. 
Besides, their anti-influenza virus activity was determined 
in cell culture, in a virus yield assay in MDCK cells and 
in a vRNP reconstitution assay in HEK293T cells. We also 
evaluated the inhibitory activity of 1–6 against a broad 
panel of DNA [i.e. herpes simplex virus type 1, vaccinia 
virus and adenovirus, evaluated in infected human embry-
onic lung fibroblast (HEL) cells] and RNA viruses (Cox-
sackie B4 virus and respiratory syncytium virus, tested in 
HeLa cells; parainfluenza-3 virus and Punta Toro virus, 
tested in Vero cells). However, they were found to be 
inactive against these diverse viruses, with the exception 
of a modest activity of 2 against herpes simplex virus-1 
(EC50 = 58 μM) and vaccinia virus (EC50 = 45 μM).
As can be seen in Table 2, compounds 2 and 4 displayed 
moderate activity in the PA-Nter enzymatic assay, with 
the catechol derivative 2 presenting the best result (IC50: 
37 μM). It is interesting to note that this compound has 
an activity profile similar to that of a 2,3-dihydroxyphenyl 
amide inhibitor that we recently reported [22], indicating 
the importance of the catechol pharmacophore for inhibi-
tion of the PA-Nter enzyme. In line with the enzymatic 
data on series 1–6, compounds 2 and 4 were also the only 
derivatives showing antiviral activity in both cell culture 
assays. Compound 2 displayed an EC99 ≥ 87 μM and 
EC90 ≥ 56 μM in the virus yield assay, and an EC50 value 
of 63 µM in the vRNP reconstitution assay. For 4, the cor-
responding values were 48, 34 and 22 µM, respectively. 
Additionally, compound 5 displayed weak inhibitory activ-
ity in the vRNP reconstitution assay, with an average IC50 
value of 150 µM.
Even if the set of data is quite limited, some prelimi-
nary conclusions can be drawn. 1 and 2 can coordinate the 
divalent magnesium ion in the B mode, using the methoxy 
and OH groups (1) or two OH groups (2); however, 1 is 
inactive, while 2 has moderate activity. The same type of 
Fig. 5  Molecular structure 
and labelling of complex 
Mg(HL1)2·2CH3OH, with 
thermal ellipsoids drawn at 
the 50 % probability level 
and dashed intramolecular 
hydrogen bonds. Bottom 
supramolecular aggregation 
of Mg(HL1)2·2CH3OH in the 
solid, with dotted hydrogen 
bonds
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substitution, i.e. moving from 4 (5-OH) to 5 (5-methoxy), 
has the same effect on biological activity [i.e. 4 is moder-
ately active; 5 has very weak activity (vRNP reconstitution 
assay) or is inactive (virus yield assay)]. It is difficult to 
correlate this effect to a different coordinating ability of the 
ligands, in particular looking at 4 and 5, which can both use 
mode A (Fig. 3). Similarly, a different coordination behav-
iour cannot explain the different activity of 3 and 4. On the 
other hand, the finding that 4 has lower activity in the enzy-
matic assay than 2 could well be related to their different 
coordination mode to the magnesium ion in the active site 
of the PA-Nter enzyme.
To further investigate the role of the thiosemicarbazone 
moiety on activity, we evaluated the biological activity of 
compound 7, the hydrazonic analogue of 2. Compound 7 
has three oxygens in the right orientation to chelate simulta-
neously two metal ions. It is worth noting that the replace-
ment of the sulphur atom of 2 with an oxygen in compound 
7 results in a slight improvement in the inhibitory activity 
against the PA-Nter enzyme, with the IC50 changing from 
37 to 24 μM. This can be related to the improved ability 
of the ligand to interact with the metal cofactors, when a 
harder donor atom is present. However, the activity of 7 
in the cellular vRNP assay is lower than that of the parent 
thiosemicarbazone 2, thus suggesting that for the thiosemi-
carbazone compounds inhibition of PA-Nter endonuclease 
is not the only mode of action. In influenza virus-infected 
cells, in fact, the antiviral activity is higher for compound 
4 than for 2, and the other TSCs are inactive. Note that, in 
cell culture (i.e. in the virus yield and vRNP reconstitu-
tion assay), 4 produces antiviral activity at concentrations 
below 50 μM, while in the enzymatic assay its IC50 value 
was 341 μM. This suggests that the suppressive effect of 
4 on influenza virus replication may not merely be related 
to direct inhibition of the endonuclease enzyme, since the 
compound may also affect other steps in the virus replica-
tive cycle. These considerations are in line with our recent 
studies [20] showing the complex biological properties of 
some molecules proposed as metal chelating inhibitors of 
the influenza virus PA endonuclease.
Computational studies
In order to explain the difference of activity between com-
pound 1 and 2, docking simulations by Gold program [44] 
were performed using the structural coordinates (pdb code 
4AWM) for the PA endonuclease in complex with epigallo-
catechin-3-gallate [14].
Table 2  Inhibitory activity of compounds 1–7 in the enzymatic assay with influenza virus PA-Nter endonuclease, or cellular influenza virus 
assays based on virus yield or vRNP reconstitution
ND not determined
a Recombinant PA-Nter was incubated with the ssDNA plasmid substrate, a Mn2+-containing buffer and test compounds. Cleavage of the sub-
strate was assessed after 2 h incubation. The IC50 represents the compound concentration (in µM) to obtain 50 % inhibition of cleavage
b MDCK (Madin–Darby canine kidney) cells were infected with influenza A virus (strain A/PR/8/34) and incubated with the compounds for 
24 h. The virus yield in the supernatant was assessed by real-time qPCR. The EC99 and EC90 values represent the compound concentrations (in 
µM) producing a 2-log10 or 1-log10 reduction in virus titer, respectively. The cytotoxicity, assessed in uninfected MDCK cells, was expressed as 
the CC50 value (50 % cytotoxic concentration, determined with the MTS cell viability assay, in µM)
c HEK293T (human embryonic kidney 293T) cells were cotransfected with the four vRNP-reconstituting plasmids and the luciferase reporter 
plasmid in the presence of the test compounds. The EC50 value represents the compound concentration (in µM) producing 50 % reduction in 
vRNP-driven firefly reporter signal, estimated at 24 h after transfection. The CC50 (in µM), i.e. the 50 % cytotoxic concentration, was determined 
in untransfected HEK293T cells by MTS cell viability assay
d DPBA, 2,4-dioxo-4-phenylbutanoic acid
Compound Enzyme assay with PA-Ntera Virus yield assay in influenza virus-infected MDCK 
cellsb
vRNP reconstitution assay in 
HEK293T cellsc
IC50 Antiviral activity Cytotoxicity Activity Cytotoxicity
EC99 EC90 MCC CC50 EC50 CC50
(1) >500 >200 >200 ≥200 >200 >200 >200
(2) 37 ≥87 ≥56 ≥100 ≥138 63 >200
(3) >500 >200 >200 >200 >200 >200 >200
(4) 341 48 34 ≥100 146 22 >200
(5) >500 >200 >200 ≥200 >200 150 >200
(6) >500 >100 >100 >200 >200 >100 >200
(7) 24 ND ND ND ND 107 >200
DPBAd 5.5 ND ND ND ND ND ND
Ribavirin ND 13 8.5 ≥200 >200 9.3 >200
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Considering that the side-chains of some residues 
change depending on which pocket the ligand is occupy-
ing, we superimposed some X-ray structures of complexes 
between PA endonuclease and known active ligands. 
We observed that the side-chain of the aminoacid Tyr24 
showed a greater movement than the other residues and for 
this reason we considered it as a flexible residue during the 
docking procedure.
First, test docking calculations, using epigallocatechin-
3-gallate, L-742,001 and 2-(4-(1H-tetrazol-5-yl)phenyl)-
5-hydroxypyrimidin-4(3H)-one (Fig. 1) were carried out 
to compare experimental and predicted binding modes and 
to validate our docking protocol. Their best docking poses 
agreed well with the experimental binding modes with 
rmsd of 0.8, 1.2 and 0.7, respectively.
Later, compounds 1 and 2 were docked and the best 
docking poses were selected and analysed by Ligplot [53] 
revealing a similar binding mode (Fig. 6a, b).
The thiosemicarbazone portions of 1 and 2 share a 
very similar network of interactions with the residues into 
the active site (hydrophobic interactions with Gly121 and 
Tyr130 and hydrogen bonds with Val122). The salicylalde-
hyde portion is able to chelate one magnesium ion in the 
same way (B mode) for both derivatives, but the 3-hydroxy 
(2) and 3-methoxy (1) groups play different roles, engaging 
different interactions both with the second magnesium ion 
Fig. 6  Docking studies of PA 
endonuclease with compounds 
1 (cyan a) and 2 (green b), 
respectively. Key residues of 
the pocket are presented using 
PyMOL [http://www.pymol.
org]. Hydrogen bonds are illus-
trated by dotted lines while the 
divalent metal ions are shown 
as purple spheres. Schematic 
drawing of types of interactions 
of the compounds 1 (c) and 2 
(d) generated using Ligplot 
[53]. Dashed lines are hydrogen 
bonds and eyelashes show resi-
dues involved in hydrophobic 
interactions
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and with some important aminoacidic residues. In particu-
lar, LigPlot analysis displays that the 3-OH of 2 forms an 
additional contact with the second metal ion and hydrogen 
bonds with the catalytic residues Asp108 and Glu119, sta-
bilizing the molecule in the active site: these interactions, 
therefore, could explain the difference of activity between 
the two compounds.
Conclusions
We have started a project focused on the synthesis and bio-
logical evaluation of chemical scaffolds that are able to 
bind one or two metal ions in the PA-Nter active site and, 
in this way, can inhibit influenza virus replication [20, 22, 
40]. From this perspective, salicylaldehyde thiosemicar-
bazones seem promising, because of their well-known 
coordinating abilities and biological properties. In the first 
evaluation reported here, positions 3, 4 and 5 of the phenyl 
ring were substituted with OH and OCH3 donor groups to 
derive a structure–activity relationship. Compounds 2 and 4 
displayed moderate activity in the PA Nter enzymatic assay 
and antiviral activity in both cell culture assays used in this 
study. In particular, compound 2, with two OH groups in 
position 2 and 3 on the phenyl ring, is the most active and 
this is in line with the results recently reported by us with 
a 2,3-dihydroxyphenyl amide inhibitor [22] and the litera-
ture regarding the use of natural polyphenols for inhibiting 
influenza virus infection [54]. Thiosemicarbazones 1–5 are 
effectively able to coordinate magnesium(II) ion, as defi-
nitely proved by the structure of Mg(HL1)2·2CH3OH, but 
it seems difficult to correlate their activity exclusively to 
this ability. For example, compound 5 is inactive, while 4 is 
moderately active, but structural differences between them 
(5-methoxy group in 5 instead of 5-OH group as in 4) do 
not imply differences in chelating properties. The different 
activity could depend not only on a different mechanism of 
action, but also on the effect that Cohen sharply describes 
as “malleable interaction” in metal coordination by metal-
loenzyme inhibitors [55], to describe the large number of 
factors (donor atom identity, orientation, electrostatics, van 
der Waals interactions,…) that are involved in the inhibi-
tion mechanism. The semicarbazone 7, that has three oxy-
gen atoms and can coordinate simultaneously two metal 
ions in the enzyme active site, is more active than the corre-
sponding thiosemicarbazone 2. Following this suggestion, 
we are now working on polyhydroxylated acylhydrazones 
to exploit their potential as antiviral inhibitors [56].
Another point that deserves closer examination is the 
difference between the data obtained for 2 and 4 using dif-
ferent assays: in the enzyme assay, 2 is more active than 
4, but the opposite was seen in virus-infected cells and the 
vRNP reconstitution assay. Compound 4 probably acts by 
different antiviral mechanisms, not only metal chelation. 
This underscores that characterization of the activity of a 
new compound is possible only if different complementary 
assays are used.
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